Telix Completes Phase 3 BiPASS Enrollment, Aligns with FDA on NDA Pathway
TLX sits 82% above its 52-week low of $6.28.
Summary
Telix completed enrollment in its Phase 3 BiPASS study and aligned with the FDA on an NDA pathway, positioning Illuccix and Gozellix for a new pre-biopsy indication that could significantly expand the prostate cancer imaging market.
Key Events · Product Development and Regulatory · TLX
-
Phase 3 BiPASS Enrollment Complete
Telix completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix and Gozellix for pre-biopsy prostate cancer imaging, the first registrational study of 68Ga-PSMA-PET in this setting.
-
FDA NDA Pathway Aligned
Telix aligned with the FDA on a New Drug Application pathway for BiPASS that, if approved, would support reimbursement as a new product and broaden patient access to gallium-based PSMA-PET imaging.
-
Market Expansion Potential
Over three million prostate biopsies are performed globally each year, with up to 75% negative; BiPASS builds on PRIMARY and PRIMARY2 data showing PSMA-PET plus MRI can reduce unnecessary biopsies by nearly 50%.
-
Next Milestone
Study data readout and potential NDA submission are the next steps; no specific dates were disclosed in the filing.
Analysis · TLX · Life Sciences
Telix finished enrolling 350 patients in its Phase 3 BiPASS study of Illuccix and Gozellix for pre-biopsy prostate cancer imaging, and has aligned with the FDA on an NDA pathway that would support reimbursement as a new product. This is the first registrational study of 68Ga-PSMA-PET imaging in the pre-biopsy setting, targeting a population of over three million annual prostate biopsies where up to 75% are negative. If successful, the data could shift PSMA-PET from staging and re-staging into initial diagnosis, expanding the addressable market for Telix's commercial imaging franchise.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $11.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $6.28 to $12.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.